Developer docs
API playgroundTry for free, no card

Search company profiles

ProteoNic

Full company profile

uuid0009e5m

Namestring
ProteoNic
Legal namestring
ProteoNic BV
Websiteurl
proteonic.nl
Company typeenum
Private
Founded yearint
2006
Descriptiontext

ProteoNic BV is a Dutch privately held biotechnology company founded in 2004 and headquartered in Leiden, Netherlands, with 11–50 employees. The company develops and licenses proprietary vector technology for mammalian cell-based biomanufacturing, anchored by its flagship 2G UNic® platform — a high-performance expression vector system engineered to enhance protein expression and productivity in mammalian production systems used to manufacture monoclonal antibodies and other biologics.

ProteoNic operates as a technology licensor rather than a drug developer, generating revenue through licensing arrangements with biotechnology and pharmaceutical manufacturers. These deals typically combine upfront fees, development milestones, and royalties on commercialized products. Its customer base historically consists of biopharmaceutical manufacturers seeking higher-yield, lower-cost production of therapeutic biologics; in November 2025 the company broadened its footprint by licensing 2G UNic® to Ginkgo Bioworks for use in a BARDA-funded Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) project valued at up to $22.2 million, targeting scalable manufacturing of anti-filovirus monoclonal antibodies (Ebola and Sudan virus) for pandemic preparedness.

The company functions as an embedded component supplier within larger biomanufacturing workflows and multi-organization consortia, positioning 2G UNic® as a foundational expression technology that partners integrate into their cell line and process development pipelines. Revenue is not publicly disclosed, and the firm has no parent company, subsidiaries, or public listing.

Short descriptiontext

ProteoNic BV is a Dutch private biotech founded in 2004 that licenses its proprietary 2G UNic® mammalian expression vector technology to biopharmaceutical manufacturers to increase yields and reduce costs of monoclonal antibody and biologic production.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeiden, Netherlands
HQ citystring
Leiden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
protein expression technology, mammalian cell systems, monoclonal antibody manufacturing, biopharmaceutical vector technology, recombinant protein production
Industry3 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Manufacturing Technology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Technology Licensing
TypeLicensing Royalties
Description

ProteoNic generates revenue by licensing its proprietary 2G UNic® vector technology to biotech and pharmaceutical companies for use in biomanufacturing. The licensing arrangements likely include upfront fees, milestone payments, and potentially royalties tied to development and commercial success.

globenewswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

ProteoNic licenses its proprietary 2G UNic® vector technology to biotech and pharmaceutical companies to enhance protein expression and productivity in mammalian cell-based production systems. The technology is applied primarily in biomanufacturing of monoclonal antibodies and other biologics, enabling higher yields, lower production costs, and improved scalability. Revenue is generated through licensing arrangements, including upfront fees, milestone payments, and royalties tied to development and commercial success.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Up to $22.2 million BARDA-funded project secured through technology licensing partnership
Product overview1 text field

ProteoNic offers a single unified technology platform built around its proprietary 2G UNic® vector technology. This flagship product is a high-performance expression vector system designed to significantly enhance protein expression and productivity in mammalian cell systems, enabling faster, scalable, and cost-effective biomanufacturing of biologics including monoclonal antibodies for therapeutic applications.

Product and service1 record
12G UNic®
CategoryCore technology platform / Bioprocess vector technology
Description

ProteoNic's proprietary high-performance vector technology designed to enhance protein expression and productivity in mammalian production systems for biopharmaceutical manufacturing, particularly for monoclonal antibody production. Licensed to biotech and pharmaceutical companies for integration into their biomanufacturing workflows.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-03
Description

ProteoNic licensed its proprietary 2G UNic® vector technology to Ginkgo Bioworks for use in a BARDA-funded project worth up to $22.2 million through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop cost-effective monoclonal antibody manufacturing for filovirus infections including Ebola and Sudan Virus.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

Partner in the BARDA-funded BioMaP-Consortium project led by Ginkgo Bioworks, focused on developing biomanufacturing approaches for monoclonal antibodies against filoviruses. Part of a multi-partner team working to scale production of anti-filovirus antibody cocktails.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

Partner in the BARDA-funded BioMaP-Consortium project led by Ginkgo Bioworks, contributing to the development of new technologies to streamline antibody production for filoviruses such as Ebola.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

Partner in the BARDA-funded BioMaP-Consortium project led by Ginkgo Bioworks, collaborating on the development of biomanufacturing innovations for monoclonal antibodies against filoviruses.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lonza is a global CDMO with proprietary expression platforms (e.g., GS Xceed) for mammalian biologics manufacturing. Overlaps with ProteoNic on expression-vector IP but operates at vastly broader scale across the full CDMO value chain.

TypeDirect peer
Description

ATUM provides synthetic biology tools, gene synthesis, and protein expression optimization platforms for biologics developers. Comparable to ProteoNic as a protein-engineering-focused platform targeting biologics manufacturing yield improvements.

TypeDirect peer
Description

Selexis offers proprietary cell line and expression technologies (SUREtechnology) for monoclonal antibody and recombinant protein production in mammalian systems. Directly comparable to ProteoNic as a vector/cell-line IP licensor serving biopharma manufacturers.

TypeBroad incumbent
Description

Cytiva supplies bioprocessing technologies, media, and expression systems used in mammalian cell-based biologics production. Adjacent incumbent serving the same downstream biomanufacturing customers as ProteoNic with a much wider portfolio.

TypeRegional player
Description

WuXi Biologics is a leading Asia-based biologics CDMO with proprietary expression and manufacturing platforms. Comparable in serving biologics manufacturers with proprietary IP, but predominantly serving Asia-based and global innovator clients from China-based operations.

TypeRegional player
Description

Samsung Biologics is a Korea-based large-scale biologics CDMO with its own cell-line and expression capabilities. Compares to ProteoNic in addressing biologics manufacturing needs but operates at the scale of a global CDMO primarily out of Asia.

TypeBroad incumbent
Description

Sartorius provides bioprocessing equipment, consumables, and cell-line development services for biologics manufacturers. Comparable end-customers and category overlap, but at much broader scale and as a public-listed equipment/platform incumbent.

TypeEmerging player
Description

Bota Bio is a synthetic biology company developing biomanufacturing platforms and engineered strains for sustainable production of proteins and other biologics. Comparable as an emerging platform player targeting biologics manufacturing with synthetic biology-driven approaches.

TypeOthers
Description

Ginkgo Bioworks is ProteoNic's anchor licensing partner and a leading synthetic biology platform that codesigns cell engineering programs for biopharma customers. Listed as OTHERS because it is a partner/ecosystem enabler rather than a direct competitor, but highly relevant to ProteoNic's go-to-market motion.

TypeBroad incumbent
Description

Through its Gibco bioproduction and CDMO arms, Thermo Fisher offers cell line development, media, and expression technologies for mAb manufacturing. A broad incumbent serving the same biologics manufacturing ecosystem as ProteoNic.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ProteoNic

Biopharmaceutical Manufacturing Technologyproteonic.nl

ProteoNic BV is a Dutch private biotech founded in 2004 that licenses its proprietary 2G UNic® mammalian expression vector technology to biopharmaceutical manufacturers to increase yields and reduce costs of monoclonal antibody and biologic production.

What ProteoNic does

ProteoNic BV is a Dutch privately held biotechnology company founded in 2004 and headquartered in Leiden, Netherlands, with 11–50 employees. The company develops and licenses proprietary vector technology for mammalian cell-based biomanufacturing, anchored by its flagship 2G UNic® platform — a high-performance expression vector system engineered to enhance protein expression and productivity in mammalian production systems used to manufacture monoclonal antibodies and other biologics.

ProteoNic operates as a technology licensor rather than a drug developer, generating revenue through licensing arrangements with biotechnology and pharmaceutical manufacturers. These deals typically combine upfront fees, development milestones, and royalties on commercialized products. Its customer base historically consists of biopharmaceutical manufacturers seeking higher-yield, lower-cost production of therapeutic biologics; in November 2025 the company broadened its footprint by licensing 2G UNic® to Ginkgo Bioworks for use in a BARDA-funded Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) project valued at up to $22.2 million, targeting scalable manufacturing of anti-filovirus monoclonal antibodies (Ebola and Sudan virus) for pandemic preparedness.

The company functions as an embedded component supplier within larger biomanufacturing workflows and multi-organization consortia, positioning 2G UNic® as a foundational expression technology that partners integrate into their cell line and process development pipelines. Revenue is not publicly disclosed, and the firm has no parent company, subsidiaries, or public listing.

ProteoNic firmographics

Firmographics
Name
ProteoNic
Legal name
ProteoNic BV
Website
https://proteonic.nl
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
ProteoNic BV is a Dutch private biotech founded in 2004 that licenses its proprietary 2G UNic® mammalian expression vector technology to biopharmaceutical manufacturers to increase yields and reduce costs of monoclonal antibody and biologic production.
Ownership category
akta.pro rank

ProteoNic industry classification

Industry
Product category
Biopharmaceutical Manufacturing Technology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Protein expression technology
  • Mammalian cell systems
  • Monoclonal antibody manufacturing
  • Biopharmaceutical vector technology
  • Recombinant protein production

Where ProteoNic is headquartered

Location

Headquarters

HQ city
Leiden
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

ProteoNic business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Technology Licensing: ProteoNic generates revenue by licensing its proprietary 2G UNic® vector technology to biotech and pharmaceutical companies for use in biomanufacturing. The licensing arrangements likely include upfront fees, milestone payments, and potentially royalties tied to development and commercial success.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

ProteoNic product offering

Product offering

Core offering

ProteoNic licenses its proprietary 2G UNic® vector technology to biotech and pharmaceutical companies to enhance protein expression and productivity in mammalian cell-based production systems. The technology is applied primarily in biomanufacturing of monoclonal antibodies and other biologics, enabling higher yields, lower production costs, and improved scalability. Revenue is generated through licensing arrangements, including upfront fees, milestone payments, and royalties tied to development and commercial success.

Product overview

ProteoNic offers a single unified technology platform built around its proprietary 2G UNic® vector technology. This flagship product is a high-performance expression vector system designed to significantly enhance protein expression and productivity in mammalian cell systems, enabling faster, scalable, and cost-effective biomanufacturing of biologics including monoclonal antibodies for therapeutic applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • 2G UNic® ProteoNic's proprietary high-performance vector technology designed to enhance protein expression and productivity in mammalian production systems for biopharmaceutical manufacturing, particularly for monoclonal antibody production. Licensed to biotech and pharmaceutical companies for integration into their biomanufacturing workflows.

Quantifiable outcome

  • Up to $22.2 million BARDA-funded project secured through technology licensing partnership

Companies that use ProteoNic

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

ProteoNic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

ProteoNic partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Ginkgo BioworkscoreOEM/ Whitelabel/ Licensing Partner · 3 November 2025ProteoNic licensed its proprietary 2G UNic® vector technology to Ginkgo Bioworks for use in a BARDA-funded project worth up to $22.2 million through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop cost-effective monoclonal antibody manufacturing for filovirus infections including Ebola and Sudan Virus.
  • Advanced BioScience LaboratoriescoreStrategic or Co-development Partner · 3 November 2025Partner in the BARDA-funded BioMaP-Consortium project led by Ginkgo Bioworks, focused on developing biomanufacturing approaches for monoclonal antibodies against filoviruses. Part of a multi-partner team working to scale production of anti-filovirus antibody cocktails.
  • Isolere Bio by DonaldsoncoreStrategic or Co-development Partner · 3 November 2025Partner in the BARDA-funded BioMaP-Consortium project led by Ginkgo Bioworks, contributing to the development of new technologies to streamline antibody production for filoviruses such as Ebola.
  • NeuImmunecoreStrategic or Co-development Partner · 3 November 2025Partner in the BARDA-funded BioMaP-Consortium project led by Ginkgo Bioworks, collaborating on the development of biomanufacturing innovations for monoclonal antibodies against filoviruses.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

ProteoNic competitors and assessment

Company assessment

Broad incumbents

  • Lonza Biologics: Lonza is a global CDMO with proprietary expression platforms (e.g., GS Xceed) for mammalian biologics manufacturing. Overlaps with ProteoNic on expression-vector IP but operates at vastly broader scale across the full CDMO value chain.
  • Cytiva: Cytiva supplies bioprocessing technologies, media, and expression systems used in mammalian cell-based biologics production. Adjacent incumbent serving the same downstream biomanufacturing customers as ProteoNic with a much wider portfolio.
  • Sartorius: Sartorius provides bioprocessing equipment, consumables, and cell-line development services for biologics manufacturers. Comparable end-customers and category overlap, but at much broader scale and as a public-listed equipment/platform incumbent.
  • Thermo Fisher Scientific (Patheon/CDMO and Gibco): Through its Gibco bioproduction and CDMO arms, Thermo Fisher offers cell line development, media, and expression technologies for mAb manufacturing. A broad incumbent serving the same biologics manufacturing ecosystem as ProteoNic.

Direct peers

  • ATUM (formerly DNA2.0): ATUM provides synthetic biology tools, gene synthesis, and protein expression optimization platforms for biologics developers. Comparable to ProteoNic as a protein-engineering-focused platform targeting biologics manufacturing yield improvements.
  • Selexis (JSR Life Sciences): Selexis offers proprietary cell line and expression technologies (SUREtechnology) for monoclonal antibody and recombinant protein production in mammalian systems. Directly comparable to ProteoNic as a vector/cell-line IP licensor serving biopharma manufacturers.

Regional players

  • WuXi Biologics: WuXi Biologics is a leading Asia-based biologics CDMO with proprietary expression and manufacturing platforms. Comparable in serving biologics manufacturers with proprietary IP, but predominantly serving Asia-based and global innovator clients from China-based operations.
  • Samsung Biologics: Samsung Biologics is a Korea-based large-scale biologics CDMO with its own cell-line and expression capabilities. Compares to ProteoNic in addressing biologics manufacturing needs but operates at the scale of a global CDMO primarily out of Asia.

Emerging players

  • Bota Bio: Bota Bio is a synthetic biology company developing biomanufacturing platforms and engineered strains for sustainable production of proteins and other biologics. Comparable as an emerging platform player targeting biologics manufacturing with synthetic biology-driven approaches.

Others

  • Ginkgo Bioworks: Ginkgo Bioworks is ProteoNic's anchor licensing partner and a leading synthetic biology platform that codesigns cell engineering programs for biopharma customers. Listed as OTHERS because it is a partner/ecosystem enabler rather than a direct competitor, but highly relevant to ProteoNic's go-to-market motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

ProteoNic social profiles

Digital presence

ProteoNic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ProteoNic leadership team

Management profile

Number of profiles

Profiles1 record

ProteoNic funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ProteoNic M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProteoNic

What does ProteoNic do?

ProteoNic licenses its proprietary 2G UNic® vector technology to biotech and pharmaceutical companies to enhance protein expression and productivity in mammalian cell-based production systems. The technology is applied primarily in biomanufacturing of monoclonal antibodies and other biologics, enabling higher yields, lower production costs, and improved scalability. Revenue is generated through licensing arrangements, including upfront fees, milestone payments, and royalties tied to development and commercial success.

Is ProteoNic a public or private company?

ProteoNic is a private company. It is classified as unknown and is currently operating.

When was ProteoNic founded?

ProteoNic was founded in 2006. It employs 11 to 50 people.

Where is ProteoNic based?

ProteoNic is headquartered in Leiden, Netherlands, in the Europe region.

How does ProteoNic make money?

One revenue line is on record: technology Licensing.

Who are ProteoNic's main competitors?

Broad incumbents on record are Lonza Biologics, Cytiva, Sartorius and Thermo Fisher Scientific (Patheon/CDMO and Gibco). Direct peers are ATUM (formerly DNA2.0) and Selexis (JSR Life Sciences). Regional players are WuXi Biologics and Samsung Biologics. Bota Bio is listed as an emerging player. Ginkgo Bioworks is listed as an others.

Does ProteoNic have an API?

No public API is recorded for ProteoNic.

What industry is ProteoNic in?

ProteoNic's product category is Biopharmaceutical Manufacturing Technology. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus TherapiesProteoNic BV announced the licensing of its proprietary 2G UNic® vector technology to Ginkgo Bioworks for use in a BARDA-funded project worth up to $22.2 million through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop cost-effective monoclonal antibody manufacturing for filovirus infections including Ebola and Sudan Virus, with a team including Ginkgo (lead), Advanced BioScience Laboratories, Isolere Bio by Donaldson, NeuImmune, and ProteoNic. ProteoNic's technology is expected to enhance expression and productivity in mammalian production systems, strengthening domestic biomanufacturing capacity for critical medical countermeasures.The Pharma LetterProteoNic 2G UNic technology licensed by Ginkgo BioworksDutch biotech company ProteoNic has licensed its proprietary 2G UNic vector technology to Ginkgo Bioworks for use in a project awarded to Ginkgo by the U.S. Biomedical Advanced Research and Development Authority (BARDA). The technology is used in biopharmaceutical and viral vector production. This licensing agreement represents a strategic win for ProteoNic, as it integrates its technology into a government-contracted biodefense or pandemic preparedness project.GlobeNewswireProteoNic Launches 2G UNic Transposon Platform to Support Superior Cell Line Productivity and Ease of UseProteoNic launched its 2G UNic transposon platform, combining its vector technology with a proprietary transposon system to improve cell line productivity. The platform shows over a two-fold titer increase, supporting production up to 10 g/L, and will be presented at BioProcess International. It also expands 2G UNic compatibility with existing third-party transposon systems.GlobeNewswireAbzena Expands Partnership with ProteoNic to Include 2G UNic® Technology as Standard Offering for All CustomersAbzena will make AbZelectPRO, combining ProteoNic's 2G UNic vector technology with its CHO cell line, the standard cell line development platform for all customers. The integration boosted protein production to 8g/L before process development and cut DNA-to-RCB timelines to 10 weeks. The technology is referenced in multiple IND applications and BLAs.PR NewswirePROTEONIC UNVEILS EARLY ACCESS PROGRAM, ELEVATING VIRAL VECTOR TITERS WITH TRANSFORMATIVE LV-2G UNIC® TECHNOLOGYProteoNic Biosciences launched the LV-2G UNic® Early Access Program on March 20, 2024, offering its next-generation lentiviral vector technology to CDMOs and biopharmaceutical companies. The program aims to enhance viral titers and manufacturing cost efficiency through ProteoNic's patented Dual Promoter system.PR NewswireNecstGen and ProteoNic report development of improved viral vectors through the application of premium 2G UNic™ technologyNecstGen and ProteoNic announced the successful development of improved lentiviral vectors achieving up to 5-fold higher functional titers using ProteoNic's 2G UNic™ premium vector technology. The collaboration, conducted at Leiden Bio Science Park in the Netherlands, aims to improve viral vector manufacturing efficiency and reduce costs for cell and gene therapies. Both companies plan to make the technology accessible through licensing, co-development opportunities, and NecstGen's CDMO services.PR NewswireProteoNic announces broadening of GigaGen's rights to 2G UNic™ TechnologyProteoNic extended its license agreement with GigaGen, granting non-exclusive worldwide commercial rights to use its 2G UNic technology for developing and manufacturing antibody drug candidates. Financial terms were not disclosed. The technology aims to boost production levels of complex proteins.PR NewswireProteoNic announces licensing of its premium 2G UNic™ Technology Platform for Production of Biologics to FyoniBioProteoNic BV and FyoniBio GmbH have entered into a worldwide, non-exclusive technology licensing agreement under which FyoniBio gains commercial rights to apply ProteoNic's 2G UNic™ protein expression technology within its proprietary CHOnamite® platform. The agreement includes milestone payments to ProteoNic on a per-product basis and will enable FyoniBio's clients to access extended cell line development options and reduced cost of goods for biologics production. The technology improves production levels of complex proteins including bispecifics and fusion proteins across mammalian cell types.PR NewswireProteoNic and NecstGen establish partnership to improve viral vector manufacturing efficiency for Gene TherapiesProteoNic and NecstGen announced a partnership to improve viral vector manufacturing for gene therapies, combining ProteoNic's 2G UNic technology with NecstGen's platforms. The collaboration aims to increase production capacity and efficiency, addressing manufacturing constraints for gene therapy development.PR NewswireProteoNic and NecstGen establish partnership to improve viral vector manufacturing efficiency for Gene TherapiesProteoNic and NecstGen, both located at Leiden Bio Science Park in the Netherlands, announced a partnership to improve viral vector manufacturing efficiency for gene therapy applications. ProteoNic will apply its 2G UNic™ technology platform while NecstGen contributes its viral vector platforms and manufacturing processes to address production bottlenecks. The companies aim to increase viral titres and production capacity to accelerate the development of novel gene therapies and ultimately benefit patients in need.